Suppr超能文献

华法林三个月疗程对静脉血栓形成发作后患者进行有效治疗是否足够?

[Is a three-month therapy with warfarin adequate for effective therapy of patients after an episode of venous thrombosis].

作者信息

Vorob'eva N M, Ermolina O V, Balakhonova T V, Dobrovol'skiĭ A B, Titaeva E V, Kirienko A I, Panchenko E P

出版信息

Ter Arkh. 2008;80(7):50-4.

Abstract

AIM

To evaluate efficacy of 3 month therapy with warfarin in patients after an episode of deep vein thrombosis (DVT) and/or pulmonary artery thromboembolism (PATE), safety of the treatment.

MATERIAL AND METHODS

26 patients after DVT/PATE aged 18-74 were treated in the hospital with non-fractionated heparin for 10-14 days followed by warfarin. The dose was selected under the control of INR up to target values 2.0-3.0. Ultrasound angioscanning of the limbs was conducted at hospitalization, on discharge, 1 and 3 months after the discharge. D-dimer was measured at discharge, 1 and 3 months after the discharge. The patients were followed up for 3 months. The following end points were considered: recurrences of deep or surface vein thrombosis, PATE recurrence, death due to PATE, hemorrhagic complications.

RESULTS

By ultrasound angioscanning significant positive results were not achieved. The level of D-dimer upon discharge was elevated in 18 (69.2%) patients (0.94, 0.41-1.69 mcg/ml). 3 month therapy with warfarin resulted in complete solution of all floting thrombs, achievement of recanalization of occlusive thrombosed deep vein in 20 (80%) patients, thrombosed vein number reduced from 4.0 to 3.0, p = 0.004. Deep vein thrombs disappeared only in 3 (11.5%) patients in 3 bmonths. Warfarin lowered D-dimer content to 0.23 mcg/ml (p < 0.001) in 1 month and to 0.12 mcg/ml (p < 0.001) in 3 moths after the discharge. 23 patients reached target 2.0-3.0 values and maintained them in therapeutic ranges. In DVT recurrence no PATE and PATE-related deaths were registered. Hemorrhagic complications arose in 5 patients, but they did not lead to warfarin discontinuation.

CONCLUSION

Warfarin is effective for secondary prophylaxis of DVT/PAT, but this therapy failed to solve thrombs in the deep veins in many patients.

摘要

目的

评估华法林3个月治疗对深静脉血栓形成(DVT)和/或肺动脉血栓栓塞(PATE)发作后患者的疗效及治疗安全性。

材料与方法

26例年龄在18 - 74岁的DVT/PATE患者在医院接受治疗,先使用普通肝素治疗10 - 14天,随后使用华法林。剂量在国际标准化比值(INR)控制下选择,使其达到目标值2.0 - 3.0。住院时、出院时、出院后1个月和3个月进行四肢超声血管扫描。出院时、出院后1个月和3个月检测D - 二聚体。对患者随访3个月。观察以下终点指标:深静脉或浅静脉血栓复发、PATE复发、PATE导致的死亡、出血并发症。

结果

超声血管扫描未取得显著阳性结果。出院时18例(69.2%)患者D - 二聚体水平升高(0.94,0.41 - 1.69 mcg/ml)。华法林3个月治疗使所有漂浮血栓完全溶解,20例(80%)患者闭塞性血栓形成的深静脉实现再通,血栓形成静脉数量从4.0减少至3.0,p = 0.004。3个月时仅3例(11.5%)患者深静脉血栓消失。出院后1个月华法林使D - 二聚体含量降至0.23 mcg/ml(p < 0.001),3个月时降至0.12 mcg/ml(p < 0.001)。23例患者达到目标值2.0 - 3.0并维持在治疗范围内。未记录到DVT复发、PATE及PATE相关死亡。5例患者出现出血并发症,但未导致停用华法林。

结论

华法林对DVT/PAT的二级预防有效,但该治疗未能使许多患者深静脉内的血栓溶解。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验